Synergy's (SGYP) Plecanatide Seen as 'Rare Gem' at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Synergy Pharmaceuticals' (SGYP) Buy Rating and $16 PT Reiterated at Rodman & Renshaw
April 20, 2016 7:34 AM EDTRodman & Renshaw reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) with a price target of $16. Analyst Raghuram Selvaraju said he is highly confident in plecanatide's prospects.
"Early yesterday, Synergy Pharmaceuticals announced that the FDA had accepted its New Drug Application (NDA) for the... More
BTIG Affirms Synergy Pharma (SGYP) at 'Buy'; Believes Plecanatide Potential Largely Being Ignored
April 19, 2016 11:41 AM EDTBTIG reaffirms Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) at Buy wth a price target of $11 after the company announced that the U.S. Food and Drug Administration (FDA) has determined that the companys New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the... More
Synergy Pharma's (SGYP) Plecanatide NDA Accepted for Review by U.S. FDA; PDUFA Date Set
April 19, 2016 6:02 AM EDTSynergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced the U.S. Food and Drug Administration (FDA) has determined that the companys New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
"This is a transformative milestone for our company and reflects our relentless commitment to bringing meaningful treatment options to patients suffering from... More
Allergan (AGN) Takeover of Synergy Pharmaceuticals (SGYP) May be Imminent - Source
April 15, 2016 3:13 PM EDTAllergan (NYSE: AGN) is in advanced talks to acquire Synergy Pharmaceuticals (Nasdaq: SGYP), according to a source claiming to have knowledge of the situation. The two sides could announce a deal as soon as next... More
